Last reviewed · How we verify
NCT06272136
Liom Non-invasive Continuous Glucose Monitor "Clinical Demo" (niCGM)
NA trial testing Clinical Demo 2.0 in Type 1 Diabetes in 80 participants. Currently enrolling.
21 July 2025
Quick facts
| Lead sponsor | Liom Health AG |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 80 |
| Start date | 23 February 2024 |
| Primary completion | 21 July 2025 |
| Estimated completion | 31 July 2025 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Clinical Demo 2.0
Conditions studied
- Type 1 Diabetes — all drugs for Type 1 Diabetes →
- Type2diabetes — all drugs for Type2diabetes →
Sponsor
Liom Health AG
Who can join
Adults 18 to 65, any sex, with Type 1 Diabetes or Type2diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-centre, multiple cohort, open study.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
2024 Diabetes Technology Meeting Abstracts
· 2025 -
A Prospective Pilot Study Demonstrating Noninvasive Calibration-Free Glucose Measurement.
Rothenbühler M, Lizoain A, Rebeaud F, Perotte A, et al · · 2026 · PMID 39881452 · DOI 10.1177/19322968251313811
Verify or expand the search:
- PubMed search for NCT06272136
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type 1 Diabetes
Currently open trials in the same condition.
- NCT07061574 — A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New On · Phase 1, PHASE2 · recruiting
- NCT07360080 — Long-Term Outcomes of Teplizumab in Routine Clinical Care · recruiting
- NCT07457580 — Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) · recruiting
- NCT07212179 — Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 · NA · recruiting
- NCT07287943 — To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes. · NA · recruiting
Other Liom Health AG trials
Trials by the same sponsor.
- NCT06406075 — Non-invasive Measurement of Glucose with Advanced Spectroscopy Techniques and Machine Learning Models · NA · completed
- NCT06097689 — A Pilot Study to Assess the Feasibility of a Novel Non-invasive Technology to Measure Changing Blood Glucose Levels in A · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06272136 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Liom Health AG
- Last refreshed: 1 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06272136.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing